ATR04-484

Phase 2Small molecule

AAzitra Inc.

ATR04-484 is one of 50 small molecule programs targeting Toxicity. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

ToxicityRecruiting

ToxicityPhase 2

Recruiting

Competition

Competitive Landscape

62 competitors in Toxicity

#DrugCompanyPhaseTrials

Zyvox

Pfizer

Approved

1 2

Norvir

AbbVie

Approved

1 3

Aldactone

Pfizer

Approved

1 4

Lipitor

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Approved

3 5

Xeloda

EEngelhard Arzneimittel GmbH & Co.KG

Approved

2 6

Ativan

BBausch Health Americas, Inc.

Approved

1 7

Prezista

WWim Janssens

Approved

1 8

Merrem

BB. Braun Medical Inc.

Approved

1 9

Atropen

FFresenius Kabi Taiwan Ltd.

Approved

1 10

Vancocin

HHikma Pharmaceuticals LLC

Approved

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 1/2Recruiting

Toxicity

NCT06830863

Clinical

Trials by Indication[1]

Toxicity1 trial

A Study to Evaluate Topical ATR04-484 for EGFRi-Associated Dermal Toxicity

Recruiting·AAzitra Inc.·Phase 1/2·NCT06830863·32 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for ATR04-484. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — ATR04-484 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for ATR04-484. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Azitra Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: AAzitra Inc.

ATR04-484

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Trials by Indication[1]

Toxicity1 trial

References

Drug Info

Quick Facts

Related News